AUTOLUS THERAPEUTICS P

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

04 Nov 2021 09:01:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress

03 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

25 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

16 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

15 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to participate in upcoming virtual investor conferences

02 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology

01 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

09 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress

05 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus

02 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer

15 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021

08 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

15 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress

11 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces an Additional Nature Publication for AUTO1

25 May 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021

21 May 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress

12 May 2021 10:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress

06 May 2021 07:00:02 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call on May 6

26 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas

20 Apr 2021 07:00:00 By Nasdaq GlobeNewswire